Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Org 34517 Adjunctive Therapy in Psychotic Major Depression
NCT00844922Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ORG-34517 in major depressive disorder with psychotic features, sponsored by Merck & Co.. Started Sep 2005; status: completed.
02
Drugs
ORG-34517
03
Conditions
major depressive disorder with psychotic features
Beyond the preview
Go deeper on NCT00844922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00844922.